Back to Search Start Over

Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers.

Authors :
Min MS
Alsarheed A
Kassamali B
Mazori DR
Schaefer M
Merola JF
Cobos G
LaChance AH
Vleugels RA
Source :
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2022 Feb; Vol. 86 (2), pp. 423-425. Date of Electronic Publication: 2021 Jul 08.
Publication Year :
2022

Abstract

Competing Interests: Conflicts of interest Dr Vleugels is a principal investigator for Pfizer. Dr Merola is a consultant and/or investigator for Abbvie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi-Regeneron, Biogen, Pfizer, and Leo Pharma. If compensation is received, it is considered honorarium. Drs Min, Alsarheed, Kassamali, Mazori, Cobos, and LaChance and Author Schaefer have no conflicts of interest to declare.

Details

Language :
English
ISSN :
1097-6787
Volume :
86
Issue :
2
Database :
MEDLINE
Journal :
Journal of the American Academy of Dermatology
Publication Type :
Editorial & Opinion
Accession number :
34246697
Full Text :
https://doi.org/10.1016/j.jaad.2021.07.003